FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3189280166> ?p ?o ?g. }

• W3189280166 endingPage "1424" @default.
• W3189280166 startingPage "1415" @default.
• W3189280166 abstract "Immune checkpoint inhibitor (ICI) therapy predisposes patients to immune-related adverse events (irAEs). Data are limited regarding the incidence, management, and outcomes of one such irAE: mucositis. In this study, we evaluated the clinical characteristics, disease course, treatment, and outcomes of ICI-mediated mucositis.This was a retrospective, single-center study of patients who received ICI therapy and developed oral mucositis at The University of Texas MD Anderson Cancer Center from January 2009 to September 2019. Inclusion criteria included age ≥18 years, a diagnosis of oral mucositis and/or stomatitis based on ICD-9 and ICD-10 codes, and therapy using CTLA-4 or PD-1/L1 inhibitors alone or combined with other agents.We identified 152 patients with a mean age of 60 years, 51% of whom were men. Of the sample patients, 73% had stage IV cancer, with melanoma the most common (28%). Median time from ICI initiation to mucositis was 91 days. The most common clinical presentation of mucositis was odynophagia and/or oral pain (89%), 91% developed CTCAE grade 1-2 mucositis, and 78% received anti-PD-1/L1 monotherapy. Compared with anti-PD-1/L1-based therapy, anti-CTLA-4-based therapy was more frequently associated with earlier onset of mucositis (73 vs 96 days; P=.077) and a lower rate of symptom resolution (76% vs 92%; P=.029); 24% of patients required immunosuppressive therapy, which was associated with longer symptom duration (84 vs 34 days; P=.002) and higher mucositis recurrence rate (61% vs 32%; P=.006). ICI interruption was associated with worse survival (P=.037). Mucositis recurrence, immunosuppressant use, and presence of other irAEs did not affect survival.For ICI-mediated mucositis, a diagnosis of exclusion has not been well recognized and is understudied. Although the clinical symptoms of mucositis are mostly mild, approximately 25% of patients require immunosuppression. Mucositis recurrence can occur in approximately 39% patients. Our results showed that ICI interruption compromises overall survival." @default.
• W3189280166 created "2021-08-16" @default.
• W3189280166 creator A5003027125 @default.
• W3189280166 creator A5003718220 @default.
• W3189280166 creator A5018451197 @default.
• W3189280166 creator A5026717218 @default.
• W3189280166 creator A5028479135 @default.
• W3189280166 creator A5039103793 @default.
• W3189280166 creator A5040796539 @default.
• W3189280166 creator A5042783072 @default.
• W3189280166 creator A5042917768 @default.
• W3189280166 creator A5050183505 @default.
• W3189280166 creator A5052738174 @default.
• W3189280166 creator A5059350381 @default.
• W3189280166 creator A5061896070 @default.
• W3189280166 creator A5073007668 @default.
• W3189280166 date "2021-12-01" @default.
• W3189280166 modified "2023-10-12" @default.
• W3189280166 title "Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer" @default.
• W3189280166 cites W1521460822 @default.
• W3189280166 cites W1556990476 @default.
• W3189280166 cites W1914776013 @default.
• W3189280166 cites W1963913768 @default.
• W3189280166 cites W2016695291 @default.
• W3189280166 cites W2063500937 @default.
• W3189280166 cites W2063576733 @default.
• W3189280166 cites W2066671159 @default.
• W3189280166 cites W2084709806 @default.
• W3189280166 cites W2097995306 @default.
• W3189280166 cites W2107150019 @default.
• W3189280166 cites W2116607009 @default.
• W3189280166 cites W2132916434 @default.
• W3189280166 cites W2143772132 @default.
• W3189280166 cites W2149050045 @default.
• W3189280166 cites W2153942285 @default.
• W3189280166 cites W2160834915 @default.
• W3189280166 cites W2179179825 @default.
• W3189280166 cites W2222086386 @default.
• W3189280166 cites W2233818050 @default.
• W3189280166 cites W2263759961 @default.
• W3189280166 cites W2265285917 @default.
• W3189280166 cites W2296047035 @default.
• W3189280166 cites W2319730639 @default.
• W3189280166 cites W2332099317 @default.
• W3189280166 cites W2417550394 @default.
• W3189280166 cites W2432017854 @default.
• W3189280166 cites W2476056549 @default.
• W3189280166 cites W2513176323 @default.
• W3189280166 cites W2529484692 @default.
• W3189280166 cites W2581935274 @default.
• W3189280166 cites W2586675028 @default.
• W3189280166 cites W2588366403 @default.
• W3189280166 cites W2605738018 @default.
• W3189280166 cites W2759963646 @default.
• W3189280166 cites W2768429453 @default.
• W3189280166 cites W2779198705 @default.
• W3189280166 cites W2783137027 @default.
• W3189280166 cites W2799996199 @default.
• W3189280166 cites W2800200585 @default.
• W3189280166 cites W2800213865 @default.
• W3189280166 cites W2801186408 @default.
• W3189280166 cites W2805482047 @default.
• W3189280166 cites W2887592099 @default.
• W3189280166 cites W2890094811 @default.
• W3189280166 cites W2891633409 @default.
• W3189280166 cites W2892119221 @default.
• W3189280166 cites W2896374103 @default.
• W3189280166 cites W2897516580 @default.
• W3189280166 cites W2898631010 @default.
• W3189280166 cites W2903072327 @default.
• W3189280166 cites W2905593807 @default.
• W3189280166 cites W2911321653 @default.
• W3189280166 cites W2911467121 @default.
• W3189280166 cites W2913054974 @default.
• W3189280166 cites W2924734345 @default.
• W3189280166 cites W2925446385 @default.
• W3189280166 cites W2931644395 @default.
• W3189280166 cites W2938549381 @default.
• W3189280166 cites W2944800712 @default.
• W3189280166 cites W2945190634 @default.
• W3189280166 cites W2947813085 @default.
• W3189280166 cites W2948598909 @default.
• W3189280166 cites W2958929637 @default.
• W3189280166 cites W2991055957 @default.
• W3189280166 doi "https://doi.org/10.6004/jnccn.2020.7697" @default.
• W3189280166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34348238" @default.
• W3189280166 hasPublicationYear "2021" @default.
• W3189280166 type Work @default.
• W3189280166 sameAs 3189280166 @default.
• W3189280166 citedByCount "8" @default.
• W3189280166 countsByYear W31892801662022 @default.
• W3189280166 countsByYear W31892801662023 @default.
• W3189280166 crossrefType "journal-article" @default.
• W3189280166 hasAuthorship W3189280166A5003027125 @default.
• W3189280166 hasAuthorship W3189280166A5003718220 @default.
• W3189280166 hasAuthorship W3189280166A5018451197 @default.
• W3189280166 hasAuthorship W3189280166A5026717218 @default.
• W3189280166 hasAuthorship W3189280166A5028479135 @default.

• next